Terns Pharmaceuticals, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2017

Location

Foster City CA US

Primary Industry

Biotechnology

About

Founded in 2017 and based in California, US, Terns Pharmaceuticals, Inc. operates as a biotechnology company that develops treatments for patients with chronic liver diseases. The company was founded by CEO Senthil Sundaram. Terns Pharmaceuticals has raised a total of USD 197 million over 3 funding rounds. In February 2021, Terns Pharmaceuticals announced the pricing of upsized Initial Public Offering for USD 127.5 million and selling 7.5 million shares at USD 17 per share on the NASDAQ. Terns Pharmaceuticals operates as a clinical-stage biopharmaceutical company that develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ program called TERN-101 a liver-distributed, nonsteroidal, non-bile acid FXR agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient intestinal FXR activation. Terns Pharmaceuticals plans to list on the Nasdaq global select market under the ticker symbol TERN.

Current Investors

Lilly Asia Ventures, OrbiMed Advisors, Vivo Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development

Website

www.ternspharma.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.